Eli Lilly and Company (LLY) on Friday reported that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% compared with endocrine therapy alone in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high-risk early breast cancer. The Phase 3 monarchE trial also demonstrated sustained long-term improvements in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS).
Verzenio is the first contemporary therapy in more than two decades to show a significant overall survival benefit in this setting. Treatment with Verzenio plus endocrine therapy also maintained a reduction in recurrence risk at seven years, continuing the deep IDFS and DRFS benefits observed at five years. Notably, 32% fewer patients receiving Verzenio plus ET were living with metastatic disease compared with those on endocrine therapy alone.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.